• Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S7070 GSK J4 HCl 90 mg/mL 90 mg/mL 90 mg/mL
S7281 JIB-04 <1 mg/mL 25 mg/mL <1 mg/mL
S7296 ML324 <1 mg/mL 43 mg/mL 3 mg/mL
S8287 CPI-455 HCl <1 mg/mL 10 mg/mL 2 mg/mL
S7234 IOX1 <1 mg/mL 37 mg/mL <1 mg/mL
S4800 Daminozide -1 mg/mL 32 mg/mL -1 mg/mL
S7581 GSK J1 <1 mg/mL 77 mg/mL <1 mg/mL
S7796 GSK2879552 2HCl 44 mg/mL 29 mg/mL <1 mg/mL
S8601 CP2 100 mg/mL -1 mg/mL -1 mg/mL
Catalog No. Information Product Use Citations Product Validations


GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.



JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively.



ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.


CPI-455 HCl

CPI-455 is a specific KDM5 inhibitor with a half-maximal inhibitory concentration (IC50) of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.



IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.



Daminozide, a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily with IC50 of 1.5±0.7 μM for KDM2A. It is at least 100-fold selective as an inhibitor of the KDM2/7 subfamily over the other demethylase subfamily members tested, with IC50s of 2 μM or less against KDM2A, PHF8, and KIAA1718 and IC50s of 127 μM for KDM3A or greater (mM range) against other demethylases.



GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.


GSK2879552 2HCl

GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.



CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.

Tags: JMJD inhibitor | JMJD modulator | JMJD chemical